Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

High materiality8/10

CytoSorbents Approves 1-for-20 Reverse Split to Satisfy Nasdaq Rule

Sep 3, 2026, 7:04 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Reverse splits typically lift per-share price and can improve Nasdaq eligibility, reducing delisting risk. While market cap remains roughly unchanged, the adjusted price can attract different buyers and improve psychological price thresholds; however, liquidity may shift and warrant/option terms will adjust, introducing near-term volatility.

AI summary

What happened, with direct paths to the underlying reporting

CytoSorbents (CTSO) announced a 1-for-20 reverse stock split to satisfy Nasdaq's $1 minimum bid price requirement. Effective Sept 8, 2026, split-adjusted shares will trade at market open, reducing shares outstanding to about 3.15 million. The move preserves ownership and market cap (excluding rounding effects) but may impact liquidity and the terms of outstanding options and warrants.

CytoSorbents to implement 1-for-20 reverse stock split.
Effective Sept 8, 2026; split-adjusted trading begins at open.
Shares outstanding drop from ~63.0M to ~3.15M post-split.
Fractional shares are not issued; rounding may affect few holders.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.